Flexion Therapeutics

Transformative Medicine... Where It Matters

  • COVID-19 Update
  • Who We Are
    • Core Principles & Values
    • Executive Committee
    • Board of Directors
    • Corporate Social Responsibility
  • Our Product
  • Our Pipeline
    • FX201
    • FX301
  • Our Science
    • Unmet Need in Osteoarthritis
    • Clinical Trials and Associated Publications
  • News
    • Press Releases
  • Investors
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Analyst Coverage
    • Contact Us
  • Careers
    • Our Culture
    • Benefits
  • Contact
    • Medical Information Request Form
    • Partnering
    • Patient Expanded Access
    • Report a Compliance Matter
  • COVID-19 Update

Our Pipeline

Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA) and post-operative pain.

Flexion Pipeline

Zilretta FX201 FX301
The information contained on this website reflects Flexion Therapeutics’ clinical development program as of March 1, 2021, and is not intended for promotional purposes. There can be no guarantee that any clinical development program reaches completion or that any indication or investigational therapy receives regulatory approval.

© 2021, Flexion Therapeutics Inc.

781.305.7777

Website Design & Development by Graphic Beans

Terms of Use Sitemap Privacy Policy

Connect with us: LinkedIn-whiteTwitter-whiteGlassdoor-white